• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

    8/8/24 4:05:00 PM ET
    $LCTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $LCTX alert in real time by email
    • 24 Month Visual Acuity Benefits from a Single Administration with OpRegen® Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit
    • Supported OpRegen for Geographic Atrophy in Phase 2a Study in Collaboration with Roche and Genentech
    • Initiated Activities Under Recently Established Services Agreement with Genentech to Support Ongoing Development of OpRegen Program
    • OPC1 Clinical Study Start Up Preparations Ongoing
    • Hosted 2nd Annual Spinal Cord Injury Investor Symposium

    Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its second quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

    "The second quarter was highlighted by clinical and preclinical execution alongside expanded awareness and data updates on our lead program," stated Brian M. Culley, Lineage CEO. "As the cell transplant field expands and continues to deliver exciting clinical outcomes, we are excited about our validating partnership and the collective expertise of the team at Roche and Genentech, as well as their ongoing leadership of the OpRegen program through presentations at scientific conferences and internal thought leader events, including Roche's Virtual Ophthalmology Day, hosted just last month. We continue to support the ongoing Phase 2a clinical study and also have initiated activities under the recently established services agreement with Genentech, enabling our partners to take advantage of our cell transplant expertise to more fully investigate the potential of the OpRegen program. In parallel, we are focused on activities in support of returning our second cell transplant program, OPC1, into the clinic this year for the treatment of spinal cord injury, a condition with growing awareness of its unmet need and commercial opportunity."

    "Importantly, our continued inclusion within the Russell 3000® Index, can help our efforts to broaden investor awareness of, and support for, Lineage as a uniquely positioned cell transplant company, one with a pharma-validated lead program and a platform technology of internally-owned clinical and preclinical assets, which is focused on growing our internally-owned cGMP capabilities in support of process and intellectual property development," added Mr. Culley.

    Recent Operational Highlights

    • RG6501 (OpRegen)
      • Continued execution under our collaboration with Roche and Genentech, a member of the Roche Group, across multiple functional areas, including support for the ongoing Phase 2a clinical study in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
      • Initiated activities under recently established services agreement with Genentech to support ongoing development of OpRegen. Lineage is providing additional clinical, technical, training and manufacturing services, fully funded by Genentech, that further support the ongoing advancement and optimization of the OpRegen program and include: (i) activities to support the ongoing Phase 1/2a study and currently-enrolling Phase 2a study; and (ii) additional technical training and materials related to Lineage's cell therapy technology platform to support commercial manufacturing strategies.
      • Positive clinical data from long-term follow-up of patients from the Phase 1/2a clinical study of OpRegen presented by David Telander, MD, PhD, Retinal Consultants Medical Group, at the 2024 Retinal Cell & Gene Therapy Innovation Summit.
        • Mean best corrected visual acuity (BCVA) gain of 5.5 letters at 24 months (n=10) in Cohort 4 patients (less advanced GA)
        • Mean BCVA gains greater among patients with improvement in outer retinal structure (n=5, +7.4 letters)
        • Maintenance or increases in external limiting membrane (ELM) and retinal pigment epithelium (RPE) layer area at 24 months observed in patients with extensive coverage of OpRegen across the areas of GA (n=5)
        • Data suggest OpRegen may counteract RPE cell dysfunction and cell loss in patients with GA by providing support to remaining retinal cells, with multi-year effects observed following a single administration
      • Preclinical results from a surgical development study of OpRegen presented by Rachel N. Andrews, DVM, PhD, DACVP, Genentech, a member of the Roche Group, at 2024 Association for Research in Vision and Ophthalmology Annual Meeting (2024 ARVO).

    • OPC1
      • DOSED (Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device) clinical study for the treatment of subacute and chronic spinal cord patient start-up activities continue.
      • Hosted the 2nd Annual Spinal Cord Injury Investor Symposium, in partnership with the Christopher & Dana Reeve Foundation.

    Balance Sheet Highlights

    Cash, cash equivalents, and marketable securities of $38.5 million as of June 30, 2024 is expected to support planned operations into Q4 2025.

    Second Quarter Operating Results

    Revenues: Lineage's revenue is generated primarily from collaboration revenues and royalties. Total revenues for the three months ended June 30, 2024 were $1.4 million, a net decrease of $1.8 million as compared to approximately $3.2 million for the same period in 2023. The decrease was primarily driven by less collaboration and licensing revenue recognized from deferred revenues under the collaboration and license agreement with Roche.

    Operating Expenses: Operating expenses are comprised of research and development (R&D) expenses and general and administrative (G&A) expenses. Total operating expenses for the three months ended June 30, 2024 were $7.3 million, a decrease of $0.9 million as compared to $8.2 million for the same period in 2023.

    R&D Expenses: R&D expenses for the three months ended June 30, 2024 were $2.9 million, a net decrease of $1.0 million as compared to $3.9 million for the same period in 2023. The net decrease was primarily driven by $0.6 million for our OPC1 program and $0.3 million for our preclinical programs.

    G&A Expenses: G&A expenses for the three months ended June 30, 2024 were approximately $4.3 million, a net increase of approximately $0.1 million as compared to $4.2 million for the same period in 2023. The increase was primarily driven by stock-based compensation expense and personnel costs.

    Loss from Operations: Loss from operations for the three months ended June 30, 2024 were $5.9 million, an increase of $0.9 million as compared to $5.0 million for the same period in 2023.

    Other Income/(Expenses): Other income (expenses) for the three months ended June 30, 2024 reflected other income of $0.1 million, compared to other expenses of ($0.2) million for the same period in 2023. The change was primarily driven by exchange rate fluctuations related to Lineage's international subsidiaries, fair market value changes in marketable equity securities, and interest income earned within our money market accounts.

    Net Loss Attributable to Lineage: The net loss attributable to Lineage for the three months ended June 30, 2024 was $5.8 million, or $0.03 per share (basic and diluted), compared to a net loss attributable to Lineage of $5.2 million, or $0.03 per share (basic and diluted), for the same period in 2023.

    Conference Call and Webcast

    Interested parties may access the conference call on August 8th, 2024, by dialing (800) 715-9871 from the U.S. and Canada and should request the "Lineage Cell Therapeutics Call." A live webcast of the conference call will be available online in the Investors section of Lineage's website. A replay of the webcast will be available on Lineage's website for 30 days and a telephone replay will be available through August 15th, 2024, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 6024260.

    About Lineage Cell Therapeutics, Inc.

    Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel or "off-the-shelf," cell therapies to address unmet medical needs. Lineage's programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient's functional activity. Lineage's neuroscience focused pipeline currently includes: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed in collaboration with Eterna Therapeutics Inc. For more information, please visit www.lineagecell.com or follow the company on X/Twitter @LineageCell.

    Forward-Looking Statements

    Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as "believe," "aim," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "can," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "tend to," or the negative version of these words and similar expressions. Lineage's forward-looking statements are based upon its current expectations and beliefs and involve assumptions that may never materialize or may prove to be incorrect. Such statements include, but are not limited to, statements relating to: the benefits of our new services agreement with Genentech and its impact on advancing the OpRegen program; the commencement of the DOSED clinical study for OPC1; that our cash, cash equivalents and marketable securities is sufficient to support our planned operations into the fourth quarter of 2025; the impacts to Lineage of our continued inclusion within the Russell 3000 Index; and the potential of our platform technology and/or manufacturing capabilities to create value. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the following risks: that we may need to allocate our cash to unexpected events and expenses causing us to use our cash, cash equivalents and marketable securities more quickly than expected; that clinical trials of our product candidates may not commence, progress or be completed as expected due to many factors within and outside of our control; that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; that OpRegen may never be proven to provide durable anatomical functional improvements in dry-AMD patients, that competing alternative therapies may adversely impact the commercial potential of OpRegen; that Roche and Genentech may not successfully advance OpRegen or be successful in completing further clinical trials for OpRegen and/or obtaining regulatory approval for OpRegen in any particular jurisdiction; that the ongoing Israel-Hamas war may materially and adversely impact our manufacturing processes, including cell banking and product manufacturing for our cell therapy product candidates, all of which are conducted by our subsidiary in Jerusalem, Israel; that Lineage may not be able to manufacture sufficient clinical quantities of its product candidates in accordance with current good manufacturing practice; and those risks and uncertainties inherent in Lineage's business and other risks discussed in Lineage's filings with the Securities and Exchange Commission (SEC). Further information regarding these and other risks is included under the heading "Risk Factors" in Lineage's periodic reports with the SEC, including Lineage's most recent Annual Report on Form 10-K filed with the SEC and its other reports, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. All forward-looking statements are expressly qualified in their entirety by these cautionary statements.

    LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (IN THOUSANDS)

    (UNAUDITED)

     

     

     

    June 30, 2024

     

    December 31, 2023

    ASSETS

     

     

     

     

    CURRENT ASSETS

     

     

     

     

    Cash and cash equivalents

     

    $

    29,622

     

     

    $

    35,442

     

    Marketable securities

     

     

    8,874

     

     

     

    50

     

    Accounts receivable, net

     

     

    235

     

     

     

    745

     

    Prepaid expenses and other current assets

     

     

    1,659

     

     

     

    2,204

     

    Total current assets

     

     

    40,390

     

     

     

    38,441

     

     

     

     

     

     

    NONCURRENT ASSETS

     

     

     

     

    Property and equipment, net

     

     

    2,018

     

     

     

    2,245

     

    Operating lease right-of-use assets

     

     

    2,584

     

     

     

    2,522

     

    Deposits and other long-term assets

     

     

    598

     

     

     

    577

     

    Goodwill

     

     

    10,672

     

     

     

    10,672

     

    Intangible assets, net

     

     

    46,540

     

     

     

    46,562

     

    TOTAL ASSETS

     

    $

    102,802

     

     

    $

    101,019

     

     

     

     

     

     

    LIABILITIES AND SHAREHOLDERS' EQUITY

     

     

     

     

    CURRENT LIABILITIES

     

     

     

     

    Accounts payable and accrued liabilities

     

    $

    5,018

     

     

    $

    6,270

     

    Operating lease liabilities, current portion

     

     

    1,069

     

     

     

    830

     

    Finance lease liabilities, current portion

     

     

    46

     

     

     

    52

     

    Deferred revenues, current portion

     

     

    9,142

     

     

     

    10,808

     

    Total current liabilities

     

     

    15,275

     

     

     

    17,960

     

     

     

     

     

     

    LONG-TERM LIABILITIES

     

     

     

     

    Deferred tax liability

     

     

    273

     

     

     

    273

     

    Deferred revenues, net of current portion

     

     

    18,543

     

     

     

    18,693

     

    Operating lease liabilities, net of current portion

     

     

    1,768

     

     

     

    1,979

     

    Finance lease liabilities, net of current portion

     

     

    68

     

     

     

    91

     

    TOTAL LIABILITIES

     

     

    35,927

     

     

     

    38,996

     

     

     

     

     

     

    Commitments and contingencies

     

     

     

     

     

     

     

     

     

    SHAREHOLDERS' EQUITY

     

     

     

     

    Preferred shares, no par value, 2,000 shares authorized; none issued and outstanding as of June 30, 2024 and December 31, 2023

     

     

    —

     

     

     

    —

     

    Common shares, no par value, 450,000 shares authorized as of June 30, 2024 and December 31, 2023; 188,824 and 174,987 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively

     

     

    467,928

     

     

     

    451,343

     

    Accumulated other comprehensive loss

     

     

    (2,470

    )

     

     

    (3,068

    )

    Accumulated deficit

     

     

    (397,158

    )

     

     

    (384,856

    )

    Lineage's shareholders' equity

     

     

    68,300

     

     

     

    63,419

     

    Noncontrolling deficit

     

     

    (1,425

    )

     

     

    (1,396

    )

    Total shareholders' equity

     

     

    66,875

     

     

     

    62,023

     

    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

     

    $

    102,802

     

     

    $

    101,019

     

    LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (IN THOUSANDS, EXCEPT PER SHARE DATA)

    (UNAUDITED)

     

     

     

    Three Months Ended June 30,

     

    Six Months Ended June 30,

     

     

    2024

     

    2023

     

    2024

     

    2023

    REVENUES:

     

     

     

     

     

     

     

     

    Collaboration revenues

     

    $

    1,098

     

     

    $

    2,871

     

     

    $

    2,285

     

     

    $

    4,992

     

    Royalties, license and other revenues

     

     

    310

     

     

     

    354

     

     

     

    567

     

     

     

    619

     

    Total revenues

     

     

    1,408

     

     

     

    3,225

     

     

     

    2,852

     

     

     

    5,611

     

     

     

     

     

     

     

     

     

     

    OPERATING EXPENSES:

     

     

     

     

     

     

     

     

    Cost of sales

     

     

    44

     

     

     

    127

     

     

     

    142

     

     

     

    246

     

    Research and development

     

     

    2,868

     

     

     

    3,873

     

     

     

    5,878

     

     

     

    8,058

     

    General and administrative

     

     

    4,363

     

     

     

    4,249

     

     

     

    9,360

     

     

     

    8,973

     

    Total operating expenses

     

     

    7,275

     

     

     

    8,249

     

     

     

    15,380

     

     

     

    17,277

     

    Loss from operations

     

     

    (5,867

    )

     

     

    (5,024

    )

     

     

    (12,528

    )

     

     

    (11,666

    )

     

     

     

     

     

     

     

     

     

    OTHER INCOME (EXPENSES):

     

     

     

     

     

     

     

     

    Interest income

     

     

    463

     

     

     

    382

     

     

     

    925

     

     

     

    792

     

    Loss on marketable equity securities, net

     

     

    (10

    )

     

     

    (150

    )

     

     

    (15

    )

     

     

    (110

    )

    Foreign currency transaction loss, net

     

     

    (378

    )

     

     

    (497

    )

     

     

    (732

    )

     

     

    (969

    )

    Other income

     

     

    19

     

     

     

    86

     

     

     

    19

     

     

     

    543

     

    Total other income (expenses)

     

     

    94

     

     

     

    (179

    )

     

     

    197

     

     

     

    256

     

     

     

     

     

     

     

     

     

     

    LOSS BEFORE INCOME TAXES

     

     

    (5,773

    )

     

     

    (5,203

    )

     

     

    (12,331

    )

     

     

    (11,410

    )

     

     

     

     

     

     

     

     

     

    Provision for income tax benefit

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    1,803

     

     

     

     

     

     

     

     

     

     

    NET LOSS

     

     

    (5,773

    )

     

     

    (5,203

    )

     

     

    (12,331

    )

     

     

    (9,607

    )

     

     

     

     

     

     

     

     

     

    Net (income) loss attributable to noncontrolling interest

     

     

    13

     

     

     

    (26

    )

     

     

    29

     

     

     

    6

     

     

     

     

     

     

     

     

     

     

    NET LOSS ATTRIBUTABLE TO LINEAGE

     

    $

    (5,760

    )

     

    $

    (5,229

    )

     

    $

    (12,302

    )

     

    $

    (9,601

    )

     

     

     

     

     

     

     

     

     

    Net loss per common share attributable to Lineage basic and diluted

     

    $

    (0.03

    )

     

    $

    (0.03

    )

     

    $

    (0.07

    )

     

    $

    (0.06

    )

     

     

     

     

     

     

     

     

     

    Weighted-average common shares used to compute basic and diluted net loss per common share

     

     

    188,813

     

     

     

    170,592

     

     

     

    185,861

     

     

     

    170,361

     

    LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (IN THOUSANDS)

    (UNAUDITED)

     

     

     

    Six Months Ended June 30,

     

     

    2024

     

    2023

    CASH FLOWS FROM OPERATING ACTIVITIES:

     

     

     

     

    Net loss attributable to Lineage

     

    $

    (12,302

    )

     

    $

    (9,601

    )

    Net loss attributable to noncontrolling interest

     

     

    (29

    )

     

     

    (6

    )

    Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc. to net cash used in operating activities:

     

     

     

     

    Loss on marketable equity securities, net

     

     

    15

     

     

     

    110

     

    Accretion of income on marketable debt securities

     

     

    (102

    )

     

     

    (516

    )

    Depreciation and amortization expense

     

     

    295

     

     

     

    276

     

    Change in right-of-use assets and liabilities

     

     

    (20

    )

     

     

    81

     

    Amortization of intangible assets

     

     

    22

     

     

     

    65

     

    Stock-based compensation

     

     

    2,432

     

     

     

    2,311

     

    Deferred income tax benefit

     

     

    —

     

     

     

    (1,803

    )

    Foreign currency remeasurement and other loss

     

     

    767

     

     

     

    1,011

     

    Changes in operating assets and liabilities:

     

     

     

     

    Accounts receivable

     

     

    508

     

     

     

    (147

    )

    Prepaid expenses and other current assets

     

     

    516

     

     

     

    (270

    )

    Accounts payable and accrued liabilities

     

     

    (1,245

    )

     

     

    (3,941

    )

    Deferred revenue

     

     

    (1,816

    )

     

     

    (5,080

    )

    Net cash used in operating activities

     

     

    (10,959

    )

     

     

    (17,510

    )

     

     

     

     

     

    CASH FLOWS FROM INVESTING ACTIVITIES:

     

     

     

     

    Proceeds from the sale of marketable equity securities

     

     

    18

     

     

     

    —

     

    Purchases of marketable debt securities

     

     

    (8,761

    )

     

     

    (12,635

    )

    Maturities of marketable debt securities

     

     

    —

     

     

     

    47,664

     

    Purchase of equipment

     

     

    (88

    )

     

     

    (444

    )

    Net cash (used in) provided by investing activities

     

     

    (8,831

    )

     

     

    34,585

     

     

     

     

     

     

    CASH FLOWS FROM FINANCING ACTIVITIES:

     

     

     

     

    Proceeds from employee options exercised

     

     

    219

     

     

     

    80

     

    Common shares received and retired for employee taxes paid

     

     

    (23

    )

     

     

    (37

    )

    Proceeds from sale of common shares

     

     

    14,070

     

     

     

    5,789

     

    Payments for offering costs

     

     

    (113

    )

     

     

    (174

    )

    Repayment of finance lease liabilities

     

     

    (27

    )

     

     

    (29

    )

    Net cash provided by financing activities

     

     

    14,126

     

     

     

    5,629

     

    Effect of exchange rate changes on cash, cash equivalents and restricted cash

     

     

    (158

    )

     

     

    (192

    )

    NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

     

     

    (5,822

    )

     

     

    22,512

     

     

     

     

     

     

    CASH, CASH EQUIVALENTS AND RESTRICTED CASH:

     

     

     

     

    At beginning of the period

     

     

    35,992

     

     

     

    11,936

     

    At end of the period

     

    $

    30,170

     

     

    $

    34,448

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240808545425/en/

    Get the next $LCTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LCTX

    DatePrice TargetRatingAnalyst
    8/20/2024$4.00Buy
    Craig Hallum
    11/2/2022$5.00Outperform
    Robert W. Baird
    6/14/2022$4.00Buy
    B. Riley Securities
    8/19/2021$8.00Outperform
    Noble Capital Markets
    More analyst ratings

    $LCTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc.

      SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

      11/21/24 8:05:56 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc. (Amendment)

      SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

      2/8/24 6:57:07 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Lineage Cell Therapeutics Inc. (Amendment)

      SC 13D/A - Lineage Cell Therapeutics, Inc. (0000876343) (Subject)

      3/25/22 5:23:02 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Lineage Cell Therapeutics with a new price target

      Craig Hallum initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00

      8/20/24 8:32:59 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on Lineage Cell Therapeutics with a new price target

      Robert W. Baird initiated coverage of Lineage Cell Therapeutics with a rating of Outperform and set a new price target of $5.00

      11/2/22 6:28:33 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B. Riley Securities initiated coverage on Lineage Cell Therapeutics with a new price target

      B. Riley Securities initiated coverage of Lineage Cell Therapeutics with a rating of Buy and set a new price target of $4.00

      6/14/22 7:59:45 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium

      Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical   Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced updates to its 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"). The 2nd SCIIS aims to accelerate development in SCI research and treatments by bringing together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived exp

      5/21/24 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

      4/1/24 8:00:00 AM ET
      $LCTX
      $SYBX
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Lineage Announces Appointment of General Counsel

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has appointed George A. Samuel III as Lineage's General Counsel and Corporate Secretary. Mr. Samuel will lead the Company's legal operations, bringing extensive corporate, transactional, intellectual property and commercial expertise which spans nearly 15 years across the life sciences and technology sectors as well as in private practice. "We are pleased to welcome George to our leadership team and look forward to his contributions as we build Lineage into a leading cell therapy and cell transplant comp

      9/1/21 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Financials

    Live finance-specific insights

    See more

    $LCTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $LCTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on May 13, 2025, by dialing (800) 7

      5/1/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its fourth quarter and full year 2024 financial and operating results on Monday, March 10, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Monday, March 10, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2024 financial and operating results and to provide a business update. Interested parties may access the conference call on Monday, March 10, 2025, by di

      3/5/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

      OpRegen® Granted Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA ReSonance™ (ANP1) Preclinical Results Presented at 59th Annual Inner Ear Biology Workshop Added to 2024 Russell 3000® Index Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update. "We were delighted to see our partners' continued commitment to the OpRegen program, in this instance by seeking

      11/14/24 4:01:00 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President and CEO Culley Brian M

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      3/12/25 5:30:54 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Howe Jill Ann

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      3/12/25 5:30:36 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by General Counsel and Secretary Samuel George A. Iii

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      3/12/25 5:30:11 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Broadwood Partners, L.P. bought $6,000,000 worth of shares (7,894,737 units at $0.76) (SEC Form 4)

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      1/28/25 7:49:41 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Howe Jill Ann bought $8,850 worth of shares (15,000 units at $0.59), increasing direct ownership by 143% to 25,500 units (SEC Form 4)

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      11/26/24 4:58:31 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • General Counsel Samuel George A. Iii bought $9,000 worth of shares (15,000 units at $0.60), increasing direct ownership by 209% to 22,184 units (SEC Form 4)

      4 - Lineage Cell Therapeutics, Inc. (0000876343) (Issuer)

      11/26/24 4:55:46 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    SEC Filings

    See more
    • Lineage Cell Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)

      5/1/25 9:09:09 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Lineage Cell Therapeutics Inc.

      DEFA14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)

      4/29/25 4:10:04 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Lineage Cell Therapeutics Inc.

      DEF 14A - Lineage Cell Therapeutics, Inc. (0000876343) (Filer)

      4/29/25 4:05:15 PM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $LCTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological conditions, today announced that it will report its first quarter 2025 financial and operating results on Tuesday, May 13, 2025, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Tuesday, May 13, 2025, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2025 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference call on May 13, 2025, by dialing (800) 7

      5/1/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

      Fully Virtual Event Scheduled for June 27, 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the Christopher & Dana Reeve Foundation, a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals impacted by paralysis, are proud to collaborate and present the 3rd Annual Spinal Cord Injury Investor Symposium ("3rd SCIIS"). This year's event aims to bring together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived experience, patient and community advoc

      4/22/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

      Lineage Participating in Panel Discussion of Novel Retina Drug Delivery Approaches at Eyecelerator@ Park City 2025 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive Officer, has been invited to join presenters from REGENXBIO Inc., Regenerative Patch Technologies, LLC, Neurotech Pharmaceuticals, Inc., and others, as part of the "I Shall Be Released: Novel Drug Delivery Approaches for Glaucoma and Retina" panel at Eyecelerator@ Park City 2025. The panel will take place on Friday, May 2, 2025 from 12:30pm to 1:30pm M

      4/21/25 8:00:00 AM ET
      $LCTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care